NEJ009 trial: A randomized phase III study of gefitinib (G) on combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2014
This article has no abstract
Epistemonikos ID: c513f8b6d14862f2748f2c6e338de68a5fbb2f9e
First added on: Feb 06, 2025